Table 1 Demographic and clinical data in identification and validation groups.

From: Identification and validation of Alzheimer’s disease-related metabolic brain pattern in biomarker confirmed Alzheimer’s dementia patients

 

Identification

Internal validation

External validation

p value

NC1

AD1

NC2

AD2

bvFTD

NC-ADNI

AD-ADNI

NC-NS

AD-NS

N

20

20

21

43

15

60

60

10

10

 

Age (y)

68 (6.5)

72.6 (8.5)

62.6 (6.6)

73 (9)

68 (11.3)

75.0 (3.9)

76.4 (5.1)

73.4 (4.8)

74.5 (5.3)

 < 0.001

Sex (m/f)

8/12

9/11

5/16

23/20

6/9

31/29

38/22

4/6

6/4

0.118

Disease duration (y)

–

4 (2.7)

–

3.3 (2)

(n = 34)

3.3 (1.3)

(n = 11)

–

5.2 (2.9)

–

3.8 (3.2)

(n = 8)

0.010

MMSE

28.7 (1.1)

18 (5.8)

29.4 (0.8)

(n = 12)

18 (4.8)

(n = 39)

19.8 (5.2)

(n = 13)

29.0 (1.2)

23.5 (2)

–

23.9 (4.2)

 < 0.001

MoCA

26.7 (2.2)

19.8 (2.5)

(n = 4)

27.6 (1.7)

(n = 13)

16.1 (5.3)

(n = 11)

14 (5.5)

(n = 4)

25.8 (2.2)

(n = 41)

17.0 (4.9)

(n = 31)

–

–

 < 0.001

MTA score (left + right)

–

3.8 (1.4)

(n = 13)

/

3.4 (1.7)

(n = 27)

–

–

–

–

–

0.371

Fazekas score

–

1 (0.6)

(n = 13)

/

0.9 (0.6)

(n = 29)

–

–

–

–

–

0.629

Alz CSF (positive/total)

0/10

20/20

0/3

43/43

0/10

0/60

60/60

–

–

 
  1. Data is presented as mean (SD).
  2. Positive Alzheimer (Alz) CSF was defined as A+/T+/N+ or A+/T+/N− (cut-offs: Aβ42 < 650 pg/ml or Aβ42/Aβ40 < 0.077, p-tau > 60 pg/ml, t-tau > 400 pg/ml) for identification and internal validation groups and as A+/T+/N+ or A+/T+/N− (cut-offs: Aβ42 < 880 pg/ml or Aβ42/Aβ40 < 0.077, p-tau > 21.8 pg/ml and t-tau > 245 pg/ml) for ADNI cohort.
  3. NC normal control, AD Alzheimer’s dementia, bvFTD behavioral variant of frontotemporal dementia, NS Northshore, ADNI Alzheimer’s Disease Neuroimaging Initiative, MMSE Mini Mental State Examination, MoCA Montreal Cognitive Assessment, MTA medial temporal lobe atrophy, CSF cerebrospinal fluid.
Back to article page